key: cord-0767622-myg8l7at
authors: Kalafat, Erkan; Heath, Paul; Prasad, Smriti; OBrien, Pat; Khalil, Asma
title: COVID-19 vaccination in pregnancy
date: 2022-05-11
journal: Am J Obstet Gynecol
DOI: 10.1016/j.ajog.2022.05.020
sha: 6a9d08e9c44c7b0494ba599ccbd6b075576d02b8
doc_id: 767622
cord_uid: myg8l7at

Despite recent endorsement from official and professional bodies, unequivocally recommending COVID-19 vaccination, hesitancy among pregnant persons remains high. The accumulated evidence clearly demonstrates that pregnant persons are a special risk group for COVID-19, with increased risk of intensive care unit admission, extracorporeal membranous oxygenation requirement, preterm birth and perinatal death. These risks are further increased with some variants of concern, and vaccination of pregnant persons reduces the COVID related increase in maternal or fetal morbidity. Data from over 180,000 vaccinated show immunization against COVID-19 with an mRNA vaccine is safe for pregnant persons. Many observational studies comparing perinatal outcomes between vaccinated and unvaccinated pregnant persons have had reassuring findings and did not demonstrate detrimental effects on pregnancy or the newborn. Immunization with mRNA vaccines does not increase the risk of miscarriage, preterm delivery, low birth weight, maternal or neonatal intensive care unit admission, fetal death, fetal abnormality or pulmonary embolism. Moreover, observational data corroborate the findings of randomized trials that mRNA vaccination is highly effective at preventing severe SARS-CoV-2 infection in pregnant persons, emphasizing that the potential maternal and fetal benefits of vaccination greatly outweigh the potential risks of vaccination. Ensuring pregnant persons have unrestricted access to COVID-19 vaccination should be a priority in every country around the globe.

The rapid accumulation of data on COVID-19 and pregnancy over the course of the pandemic resulted in many recommendations from professional bodies, which may in retrospect seem

The susceptibility of pregnant women to severe disease, mechanism of adverse effects on 113 pregnancy outcomes and the possibility of vertical transmission are yet to be fully ascertained.

However, the accumulated body of evidence confirms that pregnant women are a special risk 115 group for COVID-19. This is due not only to the direct effects of COVID-19 on pregnancy but 116 also to the indirect effects of the pandemic, such as barriers to healthcare access impacting 117 pregnancy outcomes. 13 The risk factors for severe disease appear to be similar to those in 118 non-pregnant people: socio-economic deprivation, increased body mass index (BMI), black 119 and minority ethnicity (BME), pre-existing co-morbidities, in particular pre-gestational 120 diabetes, hypertension or chronic lung disease, and increased maternal age. 14-18 One 121 pregnancy specific risk factor is timing of infection; women in their third trimester are more A common concern for women is pregnancy loss following vaccination. A preliminary report 316 by the CDC showed the observed spontaneous miscarriage rate following vaccination (12.6%)

Other studies comparing adverse outcomes between vaccinated and unvaccinated women 333 did not demonstrate an increased risk for almost all reported perinatal outcomes. 45,46,50 334 Intrapartum fever was reported to be slightly higher in vaccinated women compared to 335 unvaccinated women (3.7 vs. 1.0%, respectively) but the association was not replicated in a 336 study by Rottenstreich et al. (3.2 vs. 3.4%, respectively). 50 The increased risk in the study by 337 Blakeway et al. was not due to an excessively increased prevalence in the vaccinated cohort 338 but rather a lower-than-expected rate in the matched unexposed cohort. 45 J o u r n a l P r e -p r o o f 

The figure is created using data and graphics from Covid 19 maternal immunization tracker 782 website. https://comitglobal.org/explore/public-health-authorities/pregnancy 783 784 J o u r n a l P r e -p r o o f

JCVI issues new advice on COVID-19 vaccination for pregnant ClinicalTrials.gov

COVID-19) -Full Text View -ClinicalTrials.gov

Food and Drug Administration. 2021. FDA Approves First COVID-19 Vaccine

Centers for Disease Control and Prevention. 2021. COVID-19 Vaccination

Preliminary Findings of mRNA Covid-19

Vaccine Safety in Pregnant Persons

NHS England » NHS encourages pregnant women to get COVID-622 19 vaccine

vaccine/#:~:text=Data%20from%20Public%20Health%20England,and%20their%20b 626 aby%20against%20coronavirus.> [Accessed

Short-term 628 maternal and neonatal outcomes, a multicentre retrospective cohort study

Receipt of mRNA Covid-19 Vaccines and 680 Risk of Spontaneous Abortion

Vaccination during Pregnancy and First-Trimester Miscarriage

Equity in coronavirus disease 2019 686 vaccine development and deployment

Professionally responsible coronavirus disease 2019 vaccination counseling of 690 obstetrical and gynecologic patients

Pregnancy 692 modifies the antibody response to trivalent influenza immunization

Antibody Response to Coronavirus Disease 695 2019 (COVID-19) Messenger RNA Vaccination in Pregnant Women

Transplacental Passage Into Cord Blood

Efficient 699 maternofetal transplacental transfer of anti-SARS-CoV-2 spike antibodies after 700 antenatal SARS-CoV-2 BNT162b2 mRNA vaccination

Coronavirus disease 2019 vaccine response in 703 pregnant and lactating women: a cohort study

Immunogenicity of COVID-19 mRNA Vaccines in 706 Pregnant and Lactating Women

SARS-CoV-2 Antibodies Detected 708 in Mother's Milk Post-Vaccination

Compromised SARS-CoV-2-specific 723 placental antibody transfer

Durability 727 of Anti-Spike Antibodies in Infants After Maternal COVID-19 Vaccination or Natural 728

Prevalence and clinical outcomes of myocarditis and pericarditis in 718,365 COVID-758 19 patients

SARS-CoV-2 760 vaccination in pregnancy: a unique opportunity for equity. The Lancet

J o u r n a l P r e -p r o o f